Retrospective Case-Control Study of Pre-Diagnosis Observational and Prescription Data in Parkinson's Disease

BackgroundThere are still no disease-modifying treatments available for Parkinsons disease (PD) despite the growing interest in trialling repurposed drugs. Retrospective analysis of real-world health records may identify early predictive biomarkers and therapeutic candidates for increasing the chances of a positive trial outcome. MethodsWe conducted a retrospective case-control study using the UK-wide Clinical Practice Research Datalink (CPRD), comparing biometric and prescription data from over 38,000 individuals diagnosed with PD to 114,000 matched controls, across 5 to 10 and 10 to 20 years prior to diagnosis. ResultsThe PD cohort was characterised by significant deviations in established biometric risk factors, including markedly elevated systolic arterial pressure, serum urea, and creatinine levels, alongside widespread alterations in metabolic and inflammatory markers. A combined risk score provided a moderate predictive accuracy (ROC AUC = 0.73) in line with published analyses. We confirmed the previously reported contrasting associations of salbutamol and propranolol with PD incidence. We further found hormonal drugs and triptan migraine medication associated with a lower PD incidence. However, these drugs had a higher prescription rate in those with lower biometric-based risk possibly confounding their positive effects against PD risk. In contrast GLP-1 receptor agonists tended to be prescribed in those with higher underlying PD risk but were associated with a lower PD incidence. ConclusionIntegrating biometric and prescription histories enables more accurate interpretation of medication-disease associations, highlighting GLP-1 receptor agonists as strong candidates for PD intervention. Our findings support a data-driven framework for early risk detection and therapeutic discovery in neurodegenerative diseases.